Abstract
Faricimab, a novel drug in the field of ophthalmology, has garnered attention because of its promising applications in the treatment of various ocular conditions. This drug, with its dual targeting of angiopoietin-2 and vascular endothelial growth factor (VEGF), is a versatile intervention for the management of neovascular and inflammatory ocular disorders. Developed through meticulous research and clinical trials, faricimab holds promise as a multifaceted solution to longstanding challenges in ophthalmology. This review provides a comprehensive analysis of the current knowledge and clinical use of faricimab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
